The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation

The Veterinary Journal
Joseph A ImpellizeriSteven E Crow

Abstract

Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did not bind or deplete canine B cells and it is unlikely that it will be added to the armamentarium of treatment options for canine lymphoma.

References

Mar 16, 2004·Veterinary Pathology·K A Coyle, H Steinberg

❮ Previous
Next ❯

Citations

Jun 18, 2014·ILAR Journal·Colleen M O'Connor, Heather Wilson-Robles
Jan 29, 2010·Journal of Reconstructive Microsurgery·David W MathesRainer Storb
Mar 10, 2016·The Veterinary Quarterly·M Zandvliet
Jan 22, 2013·Veterinary Dermatology·Pamela D Martin, David J Argyle
Feb 24, 2015·The Journal of Small Animal Practice·D R KillickB Catchpole
Mar 15, 2015·Veterinary Immunology and Immunopathology·Sarah M RueMarc Nasoff
Dec 31, 2014·Cancer Immunology, Immunotherapy : CII·Federica RiccardoFederica Cavallo
Aug 10, 2016·Veterinary and Comparative Oncology·D J Argyle, E Pecceu
Jul 1, 2013·Veterinary Pathology
Oct 11, 2016·Cellular & Molecular Immunology·Rita DiehlJohannes Boltze
Dec 30, 2016·Journal for Immunotherapy of Cancer·Jiwon S ParkRobert J Canter
Jul 12, 2020·Scientific Reports·Takuya MizunoMasaya Igase
Sep 25, 2018·Veterinary and Comparative Oncology·Kosei SakaiNaoaki Matsuki
Mar 12, 2021·Advanced Drug Delivery Reviews·Lisa A Mestrinho, Ricardo R Santos
Aug 24, 2021·Frontiers in Immunology·Hans Klingemann
Sep 14, 2021·Frontiers in Veterinary Science·Joana N R DiasFrederico Aires-da-Silva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.